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Mycophenolate mofetil is an immunosuppressive agent that
blocks purine biosynthesis, inhibits T and B-lymphocyte and
mesangial proliferation. Mycophenolate mofetil is not
nephrotoxic like calcineurin inhibitors and is widely used in
solid-organ transplantation. Recently, mycophenolate mofetil
has been introduced in the treatment of autoimmune
diseases and primary glomerulopathies. This review analyzes
the literature currently available on the treatment of primary
glomerulopathies with mycophenolate mofetil. Encouraging
results have been obtained in minimal change nephropathy
where it may help to reduce the use of steroids in these
patients who are often very young. The results obtained in
medium and high risk patients with focal segmental
glomerulonephritis and idiopathic membranous
nephropathy were less encouraging. Conflicting results have
been reported on IgA nephropathy in controlled trials. None
of these studies attained level A evidence, meaning that
randomized control trials of sufficient statistical significance
are necessary to estimate the real effectiveness of
mycophenolate mofetil in primary glomerulopathies.
Kidney International (2008) 73, 154–162; doi:10.1038/sj.ki.5002653;
published online 7 November 2007
KEYWORDS: focal segmental glomerulosclerosis; idiopathic membranous
nephropathy; IgA nephropathy; minimal change nephropathy; mycophe-
nolate mofetil; steroids
Mycophenolate mofetil (MMF), a prodrug of mycophenolic
acid (MPA), is an immunosuppressive agent that blocks
purine biosynthesis by inhibiting the enzyme inosine
monophosphate dehydrogenase (IMPDH). MMF inhibits
T- and B-lymphocyte proliferation, induces apoptosis of
activated T-lymphocytes, reduces synthesis of antibodies, and
may decrease the migration of inflammatory cells into
glomeruli after antibody deposition.1 MMF does not induce
nephrotoxicity and is relatively well tolerated when compared
to other immunosuppressive drugs, such as cyclosporine A,
tacrolimus,2 cyclophosphamide, or azathioprine (AZA).3
MMF is widely used in solid-organ transplantation,4 in
several autoimmune diseases,5–8 and primary glomerulopa-
thies. This review examines the evidence currently available
on the rationale of treatment, efficacy, and toxicity of MMF
in the treatment of primary glomerulopathies.
RATIONALE FOR USE IN GLOMERULOPATHIES
MPA was isolated from a Penicillium culture by Gosio9 in
1893. In 1913, Alsberg and Black10 gave the substance
of its name, and in 1952 Birkinshaw et al. outlined its
structure.11 In 1969, Franklin and Cook12 described MPA’s
mechanism of action as an IMPDH inhibitor leading to the
inhibition of the conversion of hypoxantine into guanine,
thus reducing DNA synthesis. MPA was found to be five
times more effective as an inhibitor of the IMPDH type II
isoform, which is expressed in activated T- and B
lymphocytes, than of the type I isoform, which is expressed
in most cell types.13
Molecular mechanism of action
MPA is a reversible competitor of IMPDH14 and induces a
structural change in IMPDH resulting in annular aggregates
associated with the inhibition of IMPDH activity.15 The
addition of guanosine triphosphate (GTP) restores IMPDH
activity and prevents the protein aggregation induced by
MPA.15 MPA produces a marked reduction of GTP in human
lymphocytes16 and in mice lymphoid tissue.17 MPA depletes
tetrahydrobiopterin and decreases nitric oxide production by
inducing nitric oxide synthase without affecting constituent
nitric oxide synthase activity. Its anti-inflammatory activity
in acute or chronic transplant rejection gives MMF a
potential mechanism of action in the treatment of auto-
immune diseases.18 In a rat model of adriamycin-induced
nephrotic syndrome, angiotensin-converting enzyme inhibitors
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and MMF attenuated glomerular nephrin19 loss and also
improved proteinuria.20
Experimental glomerular disease
In an ischemic sample of uninephrectomized hypertensive
rats whose renal pedicle was clamped for 45 min, MMF-
treated rats had lower proteinuria and reduced glomerulo-
sclerosis than placebo rats.21 Enalapril treatment in experi-
mental adriamycin-induced nephrotic syndrome significantly
reduced proteinuria. A moderate antiproteinuric effect was
obtained with MMF and, unexpectedly, losartan did not
influence proteinuria even when given in addition to
enalapril.22 Proteinuria significantly improved in obese
Zucker rats treated with MMF or in combination with
losartan.23 In anti-Thy1 rats, MMF or enalapril without
immunosuppression improved proteinuria. Combined MMF
and enalapril treatment was not superior to single drug
therapy.24 MMF and angiotensin-converting enzyme inhibi-
tors appeared to be equally effective in experimental models
of proteinuria.
MYCOPHENOLATE VS AZA
Because lymphocytes have no salvage pathway for purine
synthesis, immunosuppression with MMF appears to be
more selective than AZA. The main side effects of MMF and
AZA are bone marrow suppression, reduction of the immune
response, particularly with CMV infection, skin malignancy,
gonadal toxicity, diarrhea, abdominal pain, vomiting, nausea,
and constipation. Three independent studies on kidney
transplants compared MMF to AZA in patients receiving
cyclosporine A and steroids.25–27 Patients receiving MMF
presented lowered biopsy-proven rejection or treatment
failure within the first 6 months when compared to AZA.
Long-term data from 66 774 USA renal transplant recipients
showed that both 4-year patient survival and graft survival
were significantly better for MMF patients than for patients
receiving AZA.28 Evidence from over 100 000 USA kidney
transplants showed that a lower rate of glomerular filtration
rate loss was associated with absence of rejection in patients
using MMF rather than AZA.29 A study on 59 patients with
lupus nephritis receiving randomly assigned maintenance
therapies with intravenous cyclophosphamide, oral AZA, or
oral MMF showed that (a) the event-free survival rate for
death or chronic renal failure was significantly higher in the
MMF and AZA groups; and (b) the incidence of hospitaliza-
tion, infections, nausea, and vomiting was lower in the
MMF and AZA groups than in the cyclophosphamide
group.30,31 A retrospective study on 10 patients with lupus
membranous nephropathy, previously treated with other
immunosuppressive regimes, showed that proteinuria, but
not serum creatinine, improved significantly when treated with
MMF.32 In a retrospective study on 86 patients with systemic
lupus erythematosus, treatment with MMF resulted in a
significant reduction in steroid dosage.33 MMF appears to be
better than AZA in kidney transplantation and a good, but not
necessarily a better alternative to AZA in lupus nephritis.
CLINICAL STUDIES OF MYCOPHENOLATE IN PRIMARY GLO-
MERULOPATHIES
The papers selected have been classified in accordance with
the grading system recommended (Table 1).34
To summarize in tabulated form the findings reported on
patients with minimal change nephropathy (MCN), focal
segmental glomerulosclerosis (FSGS), and idiopathic mem-
branous nephropathy (IMN), remission status was classified
according to the following definitions: complete remission
meant a reduction of proteinuriao0.3 g day1 or protein-to-
creatinine ratio (Up/c) o0.3, with serum creatinine within
10% of its baseline value; partial remission signified at least a
50% reduction of proteinuria with total proteinuria
o3 g day1 or Up/co2.5 and serum creatinine within 10%
of its baseline value; resistant meant a p50% increase of
proteinuria or any reduction of proteinuria but 43 g day1,
with serum creatinine within 10% of its baseline value;
deterioration was any increase of proteinuria X50% and/or
increase of serum creatinine 410% from its baseline value.
For Mendiza´bal et al.35 definitions have been used according
to the method specified in their paper: complete remission
meant reduction of proteinuria p4 mg per m2 per h with
normal serum albumin, that is 43 g per100 ml on 3 non-
consecutive days in the first month after treatment with
MMF and prednisone induction; partial remission was
persistence of proteinuria with normal serum albumin, that
is 43 g per100 ml; relapse meant presence of proteinuria
using urine dipsticks (Albustix þ þ þ ) on 3 non-con-
secutive days. Effectiveness of MMF treatment was defined as
complete remission (proteinuria below 0.3 g die1) or partial
remission (50% reduction in 24 h proteinuria). Failure of
treatment with MMF was defined as severe (end-stage renal
failure or persistence of proteinuria that exceeded the
baseline value by 50%) or significant (decline of 25% or
more in the inulin clearance or 0.5 mg per100 ml increase of
serum creatinine in relation to baseline values).
Minimal change nephropathy
The results of four uncontrolled studies classified between
D210 and D335–38 (Table 1) evidence levels have been
summarized in Tables 2 and 3.
Mendiza´bal et al.35 reported on MMF treatment in 26
children with idiopathic nephrotic syndrome including 11
cases of steroid/cyclosporine-dependent MCN. The mean
dose required was 624±136 (s.d.)mg per m2 per 12 h and
maintained mean C0-MPA blood levels of 2.9±1.17
(s.d.)mg ml1 (range 1.2–5.9 mg ml1). Mean duration of
MMF treatment was 8.5±3.6 (s.d.) months. The 11 patients
with MCD were treated exclusively with cyclophosphamide
for 8 weeks before MMF without any benefit, followed by
cyclosporine A for 6–51 months. All 11 patients achieved full
remission after prednisone induction. Five patients received
prednisone (0.5–1 mg kg1 on alternate days) and MMF for
6–9 months: three maintained remission for over 6 months
without immunosuppressive treatment (that is MMF,
cyclosporine A or steroids) and two patients maintained
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remission without immunosuppressive treatment for 2–6
months. Six patients received prednisone (0.5–1 mg kg1 on
alternate days) and MMF for 6–19 months and relapsed after
treatment.
Gellermann and Querfeld36 reported data on seven
children with idiopathic nephrotic syndrome and histological
signs of cyclosporine A nephrotoxicity, including six patients
with MCN. Discontinuation of cyclosporine A (mean
treatment time was 67.4 months, range 18–100 months)
increased 51Cr-EDTA clearance and effective renal plasma
flow. Steroids were used to induce remission, which was
successfully maintained by MMF for a median treatment
period of 12.7 months in five out of six patients. MMF was
given at 500 mg m2 twice daily and was modified to achieve
C0-MPA blood levels between 1.5 and 4.5 mg ml
1. At the
time of relapse, the patient had MPA trough levels at
1mg ml1 (target MPA trough levels 1.5–4.5 mg ml1).
Day et al.37 reported their experience of seven resistant
idiopathic nephrotic syndrome cases, five with MCN. The
MCN patients received initial treatment with prednisolone
and four out of five were also treated with cytotoxic agents.
Cyclosporine A was administered without benefit in all
patients before MMF was initiated. Two patients showed
histological signs of cyclosporine A toxicity. MMF was
administered in doses of 1 g twice a day. During an average
follow-up of about 25 months, full remission was observed in
all patients and relapses occurred only in two cases of non-
compliance with MMF or reduction of the steroid dose.
Complete remission was resumed when compliance with
MMF improved or when the prednisolone dosage was
increased. Prednisolone was always administered at the start
of MMF and the median (range) dose was 40 mg day1
(30–60 mg day1). After 12 months of therapy with MMF, the
prednisolone dosage fell to 7.5 mg day1 (0–40 mg day1)
meaning that at least one patient was steroid-free.
Choi et al.38 reported data on seven patients with MCN.
Five out of seven had nephrotic-range proteinuria and all
were dependent on steroids and/or cyclosporine A treatment.
In the majority of patients, MMF was initiated at 0.5–0.75 g
b.i.d. and increased to 0.5 g t.i.d. or 1.0 b.i.d. as appropriate
or tolerated. In most patients with advanced renal failure,
MMF was limited to 1.5 g or less daily. During a mean follow-
up of 9.1 months, complete remission was observed in three
out of five nephrotic patients, one out of seven patients
achieved partial remission and three out of seven were
resistant to MMF treatment.
Focal segmental glomerulosclerosis
The results of four published uncontrolled studies, classifying
D235,38,39 and D340 (Table 1) evidence levels, have been
summarized in Tables 4 and 5.
Mendiza´bal et al.35 reported on MMF treatment in 26
children with idiopathic nephrotic syndrome including 13
patients with FSGS. Previous immunosuppression had
consisted of prednisone, cyclophosphamide, and cyclosporine
Table 1 | Grading system for evidence-based
recommendations34
Grade Level of evidence 
A
A randomized controlled trial (RCT) that demonstrated a statistically
significant difference in at least one important outcome or, if the
difference is not statistically significant, an RCT that can exclude
a 25 % difference in relative risk with 80 % power, given the
observed results. 
B Best level of evidence is an RCT that does not fulfil grade A criteria. 
C
Best level of evidence is a non-randomized trial with
contemporaneous controls selected by some systematic method
or a subgroup analysis of a randomized trial. 
D
The best level of evidence is lower than level C, includes expert
opinion and one of the following:  
1. A before-after study or case series of at least 10 patients with
    historical controls or controls drawn from other studies;  
2. Case series of at least 10 patients without controls; 
3. Case reports fewer than 10 patients. 
Table 2 | Baseline characteristics of minimal change nephropathy patients treated with MMF
Age,
years 
Associated
immunosuppression
Tx duration,
months 
Reference 
N˚ M±SD Drug N˚ M±SD
MMF,
dosage 
Mendizábal S,
2005 [35] D2. 11 10.7±3.8 P 11 8.5±3.6 600 mg/m
2/12 h
Gellermann J, 
2004 [36] 
D3. 6 a12.7 (9-16) ST 6 a25.4 (15.3-39) 500 mg/m2/12 h
Day JD,
2002 [37] D3. 5 25.4±5.5 PD 5 13.2±2.8 1 g/12 h
MP 2Choi MJ, 
2002 [38] D3. 7
a41 (23-74)
P 4
9.1±7.8 0.5-1 g/12 h 
Evidence
level [34]
Patients
(Total = 29)
MMF, mycophenolate mofetil; MP, methylprednisolone; P, prednisone; PD, prednisolone; ST, steroid induction; Tx, treatment.
aMedian age and follow-up (range) were calculated on seven children: six with minimal change nephropathy and one with focal segmental glomerulosclerosis.
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A. MMF was given to FSGS patients for a mean period of 12
months as an alternative treatment to cyclosporine A. Nine
out of 13 patients achieved a full remission, one patient
remained in remission after complete drug withdrawal for
more than 6 months. MMF dosage and duration are as
previously reported for MCN. All patients also received
prednisone induction with 60 mg per m2 per day for 4 weeks
followed by prednisone 40 mg m2 for 2 days for 4 weeks.
Prednisone was discontinued in nine steroid-dependent
patients after 4 weeks, whereas it was combined with MMF
in four steroid-resistant patients (0.5–1 mg kg1 prednisone
on alternate days). Partial remission was obtained in 1 out of
13 patients and 3 patients were resistant to MMF. These four
patients had not responded to previous treatment with
prednisone or cyclosporine A.
Cattran et al.39 reported an open-label, 6-month trial in 18
FSGS patients who were resistant to steroids. MMF was
initiated at 500 mg b.i.d. and gradually increased to 1 g b.i.d..
MMF was administered for 6 months and average follow-up
lasted 9.2 months. All patients received MMF combined with
prednisone and angiotensin blockade was administered to 2
out of 18 patients. None of them recovered completely; 4 out
of 18 patients showed partial remission. Nine out of 18
patients were resistant to MMF and renal function deterio-
rated in five patients.
Montane´ et al.40 reported on nine patients with FSGS. At
the time of the study (seven patients were between 6 and 16
years of age and two patients were 21 and 24 years old,
respectively), MMF was initiated at 250–500 mg m2 per day
with a maximum dose of 2 g day1 given to the older
members. MMF was administered for an average of 36
months combined with angiotensin blockade and all patients
were treated beforehand with weekly intravenous methyl-
prednisolone (15 mg kg1 per week) for 4–8 weeks. None of
them achieved a full remission and only the 21-year-old
patient showed partial remission. Two patients were resistant
to MMF and renal function deteriorated in six patients.
Choi et al.38 published a retrospective study on 18 adult
patients with FSGS. MMF was combined with steroids in 12
out of the 18 patients, and 17 patients (94%) also received
angiotensin-converting enzyme inhibitor or angiotensin
receptor blocker therapy. MMF dosage and duration are as
Table 3 | Effectiveness of MMF in patients with minimal change nephropathy
Serum creatinine,
mg/dL 
Proteinuria Remission rate
Basal End Basal End Complete Partial Resistant Deterioration
Reference 
M±SD M±SD N˚
aMendizábal S,
2005 [35] 
NA b> 85
>40 mg/m2/h,
Alb<2.5 g/dL NA d11 0 0 0
Gellermann J, 
2004 [36] 
c~ 90 c116±27 NA NA 6 0 0 0
Day JD,
2002 [37] NA NA NA NA 5 0 0 0
Choi MJ,
2002 [38]  1.1±0.4 1.0±0.3
e4.1±2.2 e1.3±2.2 3 1 3 0
MMF, mycophenolate mofetil; Complete, complete remission defined as proteinuria less than 0.3 g die1 or urine protein-to-creatinine ratio (Up/c)o0.3 with serum creatinine
within 10% of its baseline value; Partial, partial remission defined as at least a 50% reduction of proteinuria and total proteinuria less than 3 g die1 or Up/co2.5 and serum
creatinine within 10% of its baseline value; Resistant, increase of proteinuriap50% or any reduction of proteinuria but still 43 g die1 with serum creatinine within 10% of its
baseline value; Deterioration, any increase of proteinuria X50% and/or increase of serum creatinine 410% from its baseline value; End, last follow-up; NA, not available.
aDefinitions from Mendiza´bal et al.35 Complete remission: reduction of proteinuria top4 mg m2 h1 with normal serum albumin (43 g dl1). Partial remission: persistence of
proteinuria with normal serum albumin (43 g dl1). Relapse: presence of proteinuria by urine dipstick (Albustix +++) on 3 nonconsecutive days; Alb, serum albumin.
bCreatinine clearance ml per min per 1.73 m2.
c51Cr-EDTA clearance ml per min per 1.73 m2.
dFive patients relapsed during the first month of treatment achieving remission early after.
eUp/c.
Table 4 | Baseline characteristics of focal segmental
Glomerulosclerosis patients treated with MMF
Patients
(Total=58)
Age,
years
Follow-up,
months 
Associated
immuno-
suppression
Reference Evidence
level [34]
N˚ M±SD M±SD Drug N˚
Mendizábal S,
2005 [35] D2. 13 11±4 12±6 P 13
Cattran DC,
2004 [39] D2. 18 45±12 9.2±4.5 P 18
Montané B,
2003 [40] D3. 9 14±6 36±11 MP 9
MP 9Choi MJ,
2002 [38] D2. 18 40±15 9±6 P 3
MMF, mycophenolate mofetil; MP, methylprednisolone; P, prednisone.
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previously reported for MCN. MMF was administered for at
least 3 months and mean follow-up was 9 months. One of the
patients achieved a complete remission with five patients
showing partial remission. Eleven of the 18 patients were
resistant to MMF and renal function deteriorated in one case.
Idiopathic membranous nephropathy
The results from three studies, where control groups were not
used, corresponding to evidence levels D238,41 and D342
(Table 1) have been summarized in Tables 6 and 7.
Polenakovic et al.42 reported on eight patients with
nephrotic syndrome and stages III and IV of IMN. Owing
to failure of previous treatment with cyclosporine A, steroids
and/or cyclophosphamide, all the patients were treated
exclusively with MMF. All patients had a wash out period
of 9 months. MMF was given at 2 g day1 for 9 months. Data
on angiotensin blockade were not reported. Twenty-four
hours urinary protein excretion showed a significant
improvement throughout MMF therapy, from nephrotic-
range proteinuria in all patients at baseline to a mean of
1.9 g day1.
Choi et al.38 reported on 17 patients with IMN. Treatment
with MMF was prescribed in cases of steroid or cyclosporine
A resistance, intolerance, and progressive renal insufficiency.
MMF dosage and duration are as previously reported for
MCN. Fourteen of the 17 patients also received angiotensin
blockade. After an average treatment of about 12 months, 2
of the 17 patients achieved a complete remission, 7 patients
Table 5 | Effectiveness of MMF in patients with focal segmental glomerulosclerosis
bSerum creatinine, mg/dL Proteinuria, g/die Remission rate 
Basal End Basal End Complete Partial Resistant Deterioration
Reference
M±SD M±SD N˚
aMendizábal S,
2005 [35] 
NA c> 85
>40 mg/m2/h,
Alb<2.5 g/dL
NA 9 1 f3 0
Cattran DC,
2004 [39] 
d1.52±0.8 d1.56±0.9 9.10±5.2 g6.83±6.13 0 4 9 5
Montané B,
2003 [40] 
c118±35 c104±37 e13±6 e,g3.5±2 0 1 2 6
Choi MJ,
2002 [38]  
2.3±1.5 2.5±1.9 e4.7±5.1 e,g2.2±2.5 1 5 11 1
Alb, serum albumin; MMF, mycophenolate mofetil; Complete, complete remission defined as proteinuria less than 0.3 g die1 or urine protein-to-creatinine ratio (Up/c) o0.3
with serum creatinine within 10% of its baseline value; Partial, partial remission defined as at least a 50% reduction of proteinuria and total proteinuria less than 3 g die1 or
Up/co2.5 and serum creatinine within 10% of its baseline value; Resistant, increase of proteinuriap50% or any reduction of proteinuria but 43 g die1 with serum creatinine
within 10% of its baseline value; Deterioration, any increase of proteinuria X50% and/or increase of serum creatinine 410% from its baseline value; End, last follow-up.
aDefinitions from Mendiza´bal et al.35 Complete remission: reduction of proteinuria top4 mg m2 h1 with normal serum albumin (43 g dl1). Partial remission: persistence of
proteinuria with normal serum albumin (43 g dl1). Deterioration=relapse: presence of proteinuria by urine dipstick (Albustix +++) on 3 nonconsecutive days.
bTo convert values to mmol per l, multiply by 88.4.
cCreatinine clearance ml per min per 1.73 m2.
dCalculated using table data from Cattran et al.39.
eUp/c.
fOne patient relapsed after first month of treatment achieving remission early after, gPo0.05 vs basal.
Table 6 | Baseline characteristics of idiopathic membranous nephropathy patients treated with MMF
Patients
(Total=41) 
Age,
years
Follow-up,
months 
MMF
monotherapy 
Associated
immunosuppression 
Reference Evidence
level [34] 
N˚ M±SD N˚ N˚ Drug N˚
Polenakovic M,
2003 [42] 
D3. 8 48.5±3 9 8 None
ST 11
CsA 2
Choi MJ,
2002 [38]
D2. 17 a54 (30-75) 12.1±7 3
Cyclo 1
Miller G,
2000 [41] 
D2. 16 53.2±18.9 6 11 ST 5
MMF, mycophenolate mofetil.
aMedian (range); ST, methylprednisolone or prednisolone; CsA, cyclosporine A; Cyclo, cyclophosphamide.
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showed partial remission, 7 patients were resistant to MMF,
and renal function deteriorated in 1 patient.
Miller et al.41 reported on 16 patients with nephrotic
syndrome and IMN. The patients failed or were intolerant to
prior treatment with steroids, cytotoxic agents, or cyclospor-
ine A. Eleven of the 16 patients were treated with MMF only,
while steroids were administered additionally to five patients.
Angiotensin blockade therapy was also used in 13 out of 16
patients. The initial dosage of MMF was 500 mg to 2 g daily,
then MMF was titrated according to leukocyte counts and
side effects, mainly gastrointestinal symptoms. After 6
months of MMF therapy, none of the patients had made a
full remission, whereas 3 out of 16 patients showed partial
remission, 8 patients were resistant to MMF, and renal
function deteriorated in 5 patients.
IgA nephropathy
The results from three controlled trials with level B43–45
evidence (Table 1) have been summarized in Tables 8 and 9.
Maes et al.43 published a report on 34 patients with IgA
nephropathy (IgAN), of whom 21 were randomized to
treatment with MMF and 13 were randomized to the control
arm. Patients randomized for immunosuppression received
MMF 1 g b.i.d. for 36 months unless doses had to be reduced
because of side effects. Angiotensin blockade was adminis-
tered to 9 out of 21 MMF patients and to 3 control subjects.
Five of the 34 patients interrupted the treatment prematurely:
3 of the 21 patients in the MMF group (one patient because
of reactivation of pulmonary tuberculosis and two patients
because of emigration), and 2 of the 13 control subjects (one
patient because of pregnancy and one patient due to
metastasized rectal carcinoma). A significant decrease in
proteinuria from baseline was observed at the end of the
study in both groups. No difference in urinary protein
excretion emerged between the MMF and the control group.
Severe treatment failure, defined as end-stage renal failure,
was observed in 2 out of 18 MMF patients and in 1 out of 11
control subjects. Significant failure of treatment, defined as a
decline in inulin clearance by 25% or more, was observed in 7
out of 18 patients in the MMF group and in 2 out 11 control
subjects. There was no difference in renal function between
the two groups.
Frisch et al.44 reported on 32 patients with IgAN, of whom
17 were randomized to treatment with MMF and 15 to the
control group. Patients randomized for immunosuppression
received MMF 1 g b.i.d. unless the dose was reduced due to
side effects. Treatment with MMF lasted 1 year and three
patients did not complete treatment due to end-stage renal
failure. All patients received angiotensin blockade therapy
Table 7 | Effectiveness of MMF in patients with idiopathic membranous nephropathy
aSerum creatinine, mg/dL Proteinuria, g/die Remission rate 
Basal End Basal End Complete Partial Resistant Deterioration 
Reference
M±SD M±SD N˚
Polenakovic
M, 2003 [42] 1.13±0.16
b 0.98±0.13b,d 4.44±0.16b 1.99±0.29b,e NA
Choi MJ,
2002 [38] 1.5±0.8 1.3±0.7
e 7.7±4.8c 3.4±3.8c,e 2 7 7 1
Miller G,
2000 [41] 2.1±1.3 2.1±1.4d 9.2±4.2 7.5±5.7d 0 3 8 5
MMF, mycophenolate mofetil.
aTo convert values to mmol per l, multiply by 88.4; Complete, complete remission defined as proteinuria less than 0.3 gdie1 or urine protein-to-creatinine ratio (Up/c) o0.3
with serum creatinine within 10% of its baseline value; Partial, partial remission defined as at least a 50% reduction of proteinuria and total proteinuria less than 3 g die1 or
Up/co2.5 and serum creatinine within 10% of its baseline value; Resistant, increase of proteinuria p50% or any reduction of proteinuria but still 43 g die1 with serum
creatinine within 10% of its baseline value; Deterioration, any increase of proteinuria X50% and/or increase of serum creatinine 410% from baseline.
bNot specified if s.d. or s.e.m.; End, last follow-up; NA, not available.
cUp/c.
dP=NS vs Basal.
ePo0.05 vs Basal.
Table 8 | Baseline characteristics of IgA nephropathy patients
treated with MMF and controls
Age, years Patients 
M±SD
Follow-up 
MMF
(Total =58) 
CTRLs
(Total=48)
Reference Evidence
level [34] 
N˚
MMF CTRLs MMF CTRLs 
Maes BD,
2004 [43] 
B a21 13 39±11 43±15 36 mts 36 mts
Frisch G,
2005 [44] 
B a17 15
b38
(19-72)
b37
(22-59) 
c54
wks
54 wks
Tang S,
2005 [45]  
B d20 20 42±3 43±3 e18 mts 18 mts
MMF, mycophenolate mofetil.
aMMF dosage: 1 g twice a day.
bMean (range).
cPatients have been treated with MMF for 52 weeks.
dMMF dosage: 2 g day1 if body weight X60 kg or 1.5 g day1 if body weight
o60 kg.
ePatients have been treated with MMF for 24 weeks; CTRLs, controls; mts, months;
wks, weeks.
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during the 54 weeks of follow-up. Some patients also received
fish oil at their own or at their physician’s discretion. No
differences were observed between the two groups at the end
of the study in variations of serum creatinine and 24 h
proteinuria values from baseline. Partial remission, defined as
a 50% reduction in 24 h protein excretion, occurred in 3 out
of 14 patients from the MMF group and in 2 out of 15
control subjects. Severe treatment failure, defined as end-
stage renal failure, occurred in 5 out of 17 from the MMF
group and in 2 out of 15 control subjects. Significant
treatment failure, defined as an 0.5 mg per100 ml increase in
serum creatinine, was observed in 10 out of 17 patients from
the MMF group and in 7 out of 15 control subjects.
Tang et al.45 reported on 40 patients with IgAN. Twenty
patients were randomized to receive MMF at a dose of
2 g day1 if body weight was X60 kg or 1.5 g day1 if body
weight was o60 kg for 24 weeks and 20 patients were
randomized as control subjects. All the patients received
angiotensin blockade throughout the study. During the
18-month study period, 16 out of 20 patients from the
MMF group and 6 out of 20 controls (P¼ 0.0019 vs MMF
group) demonstrated remission from proteinuria, defined as
proteinuria below 0.3 g day1 or a 50% reduction in 24 h
proteinuria.
DISCUSSION
MMF has recently been introduced as an immunosuppressive
option in the treatment of autoimmune diseases. The
rationale underlying MMF therapy for immune-related
nephropathies appears sound in terms of molecular mechan-
isms, cellular, animal, and human studies, prevention of
acute rejection and long-term follow-up in kidney trans-
plantation.3,14–34 However, its effectiveness in primary
glomerulonephritis has not yet been established. It also
remains to be established whether, in terms of outcome and
side effects, MMF is really superior to AZA in the treatment
of chronic glomerulonephritis.
MMF doses administered in the published studies varied
greatly. For example, in studies on children, MMF doses for
MCN or FSGS ranged from 250 mg per m2 per day to about
750 mg per m2 per twice daily.35–40 All authors titrated MMF
according to C0-trough levels between 1.2 and 5.9 mg ml
1
generally reporting minor disturbances such as gastrointest-
inal symptoms or acne. In studies of MMF in adults, doses in
patients with MCN,36 FSGS,36–37 IMN,36,39–40 or IgAN41–43
ranged between 500 mg to 2 g daily in two or three separate
doses.
The duration of treatment was also highly variable,
ranging from 1–2 months33,36–38 to 36–39 months.34,42 This
is important because the reduction in proteinuria in patients
who received MMF for only a few months could possibly be
due to a carryover effect from previously administered
medications.
The current status of clinical experience with MMF on
primary glomerulopathies still appears to be very prelimin-
ary. Some studies have demonstrated the effectiveness of
MMF in reducing proteinuria. All the papers reviewed
include D2 and D3 evidence levels, which implies that
randomized control studies on MMF in glomerulopathy still
have to be carried out. Overall, in most studies of nephrotic
patients with FSGS and IMN, MMF appears to have been
used in patients who were refractory or intolerant to steroids,
cyclosporine A, or cyclophosphamide. In patients with FSGS
(Table 5)33–36 or IMN (Table 7),36,39–40 MMF treatment was
associated with a partial response or resistance. Renal
function deteriorated in some of the latter patients. It should
be stated that disease was at an intermediate or advanced
stage in all these patients and that MMF was introduced after
all other immunosuppressive drugs had failed. It will be
interesting to study the effects of MMF in de novo patients
with FSGS or IMN. angiotensin-converting enzyme inhibi-
tion and ANG II receptor blockers were also combined with
steroids and MMF, but it is difficult to evaluate their real
impact on proteinuria.
Table 9 | Effectiveness of MMF in patients with IgA nephropathy
Treatment effectiveness Treatment failure
Complete remission Partial remission Severe Significant 
• Urinary protein excretion 
   below 0.3 g/die [Tang S] 
• 50% reduction in 24 h
   protein excretion
   [Frisch G, Tang S] 
• ESRF [Frisch G, Maes BD]
• Persistence of urinary protein
   excretion that exceeded 50%
   of the baseline value 
• Decline of 25% or more in
   the inuline clearance [Maes BD]
• 0.5 mg/dL increase of SCr
   from baseline [Frisch G] 
MMF CTRLs MMF CTRLs MMF CTRLs MMF CTRLs 
Reference
N˚ N˚ N˚ N˚
Maes BD,
2004 [43] NA NA NA NA 2/18 1/11 7/18 2/11
Frisch G,
2005 [44] NA NA 3/14 2/15 5/17 2/15 10/17 7/15
Tang S, 
2005 [45]  12/20 1/20 4/20 5/20 4/20 14/20 NA NA
MMF, mycophenolate mofetil; NA, not available; ESRF, end-stage renal failure; SCr, serum creatinine; CTRLs, controls.
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Complete remission in MMF-treated patients was only
observed in children or adults with IMN (Table 3).33–35 These
results are encouraging and should lead to randomized
studies in such patients and in de novo patients.
Conflicting results have been reported in the three level B
studies on MMF in IgAN.42–44 Only one study reported
positive results showing complete or partial remission from
proteinuria in 80% of patients on MMF therapy and severe
treatment failure in 70% of the controls.43 Although patients
from all studies were assigned to treatment after randomiza-
tion, data on renal pathology are not available. Randomized
trials designed according to histopathological lesions should
help to solve the dilemma.
In conclusion, MMF appears to be a potential alternative
to steroids, calcineurin inhibitors, and cytotoxic agents in
primary glomerulopathies, mainly because of the absence of
nephrotoxicity and the generally minimal side effects.
However, trials providing level A evidence are needed in
order to fully evaluate the real effectiveness of MMF in
primary glomerulopathies.
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